Coya Thera reports positive data; SanaCurrents closing out coverage | $COYA, $INSM
ALS patients demonstrated likelihood of benefitting from investigational drug
Coya Therapeutics (NASDAQ:COYA) recently published confirmatory analyses of blood biomarker data from a cross sectional cohort of sporadic Amyotrophic lateral sclerosis (ALS) patients (n=30) and healthy controls (n=10) who participated in the company’s recent clinical trials. The published results identified the ALS patients most likely to benefit from COYA 302, Coya’s investigational drug to treat ALS.
COYA 302 works to reduce inflammation by boosting the activity of regulatory T-cells, a type of anti-inflammatory immune cells also known as Tregs.
ALS patients demonstrated a strong correlation between a clinical response and levels of 4-HNE and inflammatory biomarkers monocyte chemoattractant protein-1 (CCL2) and interleukin (IL-18), validating the use of Treg-enhancing therapies, according to Coya.
SanaCurrents issued a June 2023 report forecasting a positive outcome for the published Coya biomarker data when the stock traded at $4.55 per share. The company’s stock traded between $4.60 per share and $4.95 per share on September 13 when SanaCurrents closed its position in Coya. SanaCurrents is discontinuing its coverage of Coya.